How can prioritizing data accelerate drug discovery?

We spoke with Zoheb Hassan, Ph.D., a Principal Consultant at Frost & Sullivan’s Healthcare and Life Sciences Practice about the complexities that define the current drug discovery landscape. His perspectives highlight the challenges in managing and packaging the increasing flood of data into actionable insights and the primary reason drug discovery is being held back—a lack of data prioritization. 

CAS: In your role, how do you help advance life sciences research and development?

CAS: What do you see as the single biggest issue holding back drug discovery today?

CAS: What is the significance of establishing a solid data foundation for drug discovery?

CAS: Are you hopeful that organizations can collaborate to solve some of the industry's biggest data challenges?

CAS: What common challenges do you see in the industry regarding data management?

CAS: How do organizational structures impact the efficiency of information sharing and data management?

CAS: Are there broader implications for data management inefficiencies within drug discovery teams?

CAS: Where do you think AI can have the most impact, and what are some of the potential pitfalls?

CAS: In such a complex environment, do you have any general solutions for how companies can overcome these challenges?

CAS: If you had a magic wand to change anything in the drug discovery process, what would you change?

Zoheb Hassan, Ph.D., has spent the past eight years as a growth strategy consultant specializing in the healthcare and life sciences sectors. He focuses on transforming market data and research into actionable insights, helping clients navigate a constantly evolving landscape influenced by emerging trends, threats, and new technologies. His expertise ensures clients stay ahead of their competition by anticipating and leveraging these market shifts into opportunities for growth. Before consulting, Zoheb earned his B.Sc., M.Sc., and Ph.D. from King’s College London, specializing in biomedical science with an emphasis on diabetes research and drugging GPCRs.